Oral Anticoagulants Market Size was valued at USD 22.76 billion in 2023. The oral anticoagulants market industry is projected to grow from USD 24.76 Billion in 2024 to USD 38.1 billion by 2032 exhibiting a compound annual growth rate (CAGR) of 5.53% during the forecast period (2024 - 2032). The upsurge in the geriatric population, the increase in cardiovascular diseases, and the growing preference for surgical procedures are the major market drivers boosting the growth of the oral anticoagulants market.
Source Primary Research, Secondary Research, MRFR Database, and Analyst Review
Bayer's oral factor Xia inhibitor Asundexian was granted a fast-track status by the FDA of the United States of America in February 2022. This drug was on trial during stage two, which might have safety advantages over other drugs.
Stony Brook Study also gave anticoagulation treatment to investigate whether D-Dimer levels reduced mortality in seriously sick patients of COVID-19 during February 2021.
Oral administration is the most popular drug delivery technique in the pharmaceutical sector. To prevent and treat atypical blood clots, oral anticoagulants work in conjunction with the human body's natural blood-thinning system. Several serious and urgent diseases have become more prevalent globally currently. Since they were first made accessible to the general public, anticoagulants have seen tremendous R&D developments. Innovative oral anticoagulants (NOACs), among other innovative treatments, have since been introduced and have succeeded tremendously. Cardiovascular diseases are one of these serious illnesses, and they are now very common all over the world, thanks in large part to changes in modern lifestyle. Heart and blood vessel illnesses, particularly those that are life-threatening, like coronary artery disease, are included in the category of cardiovascular diseases.
Recently, several other drugs referred to as innovative oral anticoagulants (NOACs) are being researched and made accessible as alternatives to warfarin. The improvement of anticoagulant medications speaks to a remarkable restorative test and marks a new evolution in the pharmaceutical sector. Therapy of venous and blood vessel thrombotic sickness. One of the key factors influencing market expansion is the rise in cardiovascular health awareness and the associated rise in innovative treatment releases. Cardiovascular therapy requires a comprehensive strategy that could lead to various drugs. However, blood thinners constitute a crucial component of that therapeutic plan. Several significant market players have introduced anticoagulants in response to the urgent medical demand for blood clot prevention.
Patients with mechanical heart valves, atrial fibrillation, a random heartbeat that increases the risk of stroke, blood clots in the limbs or the lungs, or other blood clusters in the veins are treated with oral anticoagulants. Oral anticoagulants have increased their market share significantly in recent years due to pharmaceutical scientists' improved understanding of the biochemical and physicochemical properties and patient compliance. Several variables are driving the expansion of these medications in the current worldwide market for blood thinners. There is a greater understanding of cardiovascular wellness and the potential consequences or detrimental effects of neglecting it. By regulating and preventing the formation of blood clots, blood thinning drugs frequently serve a critical role in protecting human cardiovascular health.
Increased awareness about cardiovascular health, as well as the corresponding increase in new therapeutic launches, is one of the crucial drivers of  market growth. Cardiovascular therapeutics entails a multifaceted approach that may result in various medications. Nonetheless, blood thinners are an essential part of that treatment regimen. Several key market leaders have introduced anticoagulants, addressing the critical needs of treatment in terms of blood clot prevention. For instance, Pfizer Inc and Bristol-Myers Squibb Company introduced the anticoagulant Eliquis (apixaban). The product sells well and has shown superior risk reductions compared to other drugs, propelling the oral anticoagulants market CAGR.
The high prevalence of cardiovascular diseases (CVD) worldwide and the increasing demand for suitable thinners are also important driving factors. Anticoagulants have undergone significant R&D advancements since they were first made available to the general public. Since then, several novel therapeutics have been introduced and have been incredibly successful, including novel oral anticoagulants (NOACs). Eliquis and Xarelto are now the two most important anticoagulants on the  market. A greater prevalence of generics and additionally anticipated launches of anticoagulant generics could hurt the market. However, the nature of cardiovascular diseases (CVD) has rendered them nearly incurable, and the rising prevalence is worsening patients' treatment options. This market, which has several unmet medical needs, is anticipated to be another critical growth driver for the  oral anticoagulants market revenue.
Based on product, the oral anticoagulants market segmentation includes novel oral anticoagulants and warfarin. The novel oral anticoagulant segment held the majority share in 2022, accounting for 65-67% of the  oral anticoagulants market revenue, owing to the increasing acceptance of novel oral anticoagulants (NOACs) in developing nations and the high preference for NOACs over warfarin. The term 'novel oral anticoagulants' (NOACs) refers to a new class of anticoagulant medications. Besides, they are safe (lower risk of major bleeding), easy to use, have no food interactions, and have a shorter half-life. The NOACs include drugs like apixaban, rivaroxaban, dabigatran, and edoxaban. These can prevent and treat pulmonary embolism, deep vein thrombosis (DVT), and atrial fibrillation/myocardial infarction. According to a June 2022 update from the Centers for Disease Control & Prevention (CDC), nearly 900,000 people ((1 to 2 per 1,000 population)) in the United States could be affected by deep vein thrombosis each year. Deep vein thrombosis also claims the lives of 60,000–100,000 Americans annually. Thus, the rising prevalence of cardiovascular diseases, venous thromboembolism (VTE), and technological advances in developing novel products are the main driving factors in the novel oral anticoagulants segment.
Based on disease indication, the  oral anticoagulants market segmentation includes atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and heart attacks. The pulmonary embolism (PE) segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. A blood clot that forms in the pulmonary arteries of the lungs and prevents blood flow is called a pulmonary embolism. This condition is potentially fatal and can lead to a more critical illness known as deep vein thrombosis (DVT). Another factor anticipated to fuel market growth is the rising prevalence of pulmonary embolism brought on by other risk factors like obesity, heart disease, and cancer.
Figure 2 Oral Anticoagulants Market, by Disease Indication, 2022 & 2032 (USD Billion)Â 
Source Primary Research, Secondary Research, MRFR Database, and Analyst Review
Further, the heart attack segment is expected to grow the fastest in the oral anticoagulants industry during the forecast period since anticoagulants are essential for preventing additional myocardial infarctions in people who have already had one heart attack. Anticoagulant therapy is advised for people with atrial fibrillation and a high risk of stroke.
Distribution channels have bifurcated the  oral anticoagulants market data into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment led the  market in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. Retail pharmacies can provide efficient services for prescription refilling.
Aside from the retail pharmacies, the online pharmacies segment is expected to have the highest  oral anticoagulants industry growth in the forecast period due to an increase in the use of online pharmacy services by various nations. Online pharmacies are becoming increasingly popular owing to their ease and convenience. According to a recent Annals of Internal Medicine study, direct-acting oral anticoagulants (DOACs) are cheaper than heparin with low molecular weight (LMWH) injections for treating cancer-associated thrombosis. When deciding on the best course of action for these patients, policymakers and physicians should use the findings as a guide. Specific cancer-related pathways may be involved, even if some mechanisms may be shared with non-malignant conditions. According to a popular theory, cancer may activate platelets and the coagulation cascade. Additionally, cancer treatments may increase this risk—again, the underlying processes are unclear.
By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North America Oral Anticoagulants market accounted for USD 9.57 billion in 2022 and is anticipated to exhibit a significant CAGR growth over the study period. The high prevalence of cardiovascular diseases requiring anticoagulant treatment, combined with new product launches throughout the region, will drive the growth of the oral anticoagulants market. According to American Heart Association research in October 2021, roughly 2,300 Americans die each day from cardiovascular diseases, an average of one death every 38 seconds. Additionally, the Centers for Disease Control & Prevention estimates that in February 2022, heart disease will be the leading cause of mortality in the United States, with about 659,000 deaths annually. This accounts for nearly 25% of all deaths in the United States. As a result of the rise in cardiovascular diseases, the demand for oral anticoagulants in the region is increasing, boosting the market. Along with these factors, the market in North America is anticipated to grow during the forecast period due to rising research and development efforts, increased awareness, and the prevalence of risk factors like obesity and diabetes among the general populace.
Further, the major countries studied in the market report are the U.S., Germany, Canada, France, the UK, Italy, Japan, India, Australia, Spain, China, South Korea, and Brazil.
Figure 3 ORAL ANTICOAGULANTS MARKET SHARE BY REGION 2022 (%)
Source Primary Research, Secondary Research, MRFR Database, and Analyst Review
The European oral anticoagulants market has the second-largest market share due to the rising incidence of cardiovascular disease, increasing the use of blood-thinning medications. For instance, the European Cardiovascular Disease Statistics show that more than 45% of all deaths in Europe are attributable to cardiovascular disease. Moreover, the existence of top pharma and biotech companies involved in therapeutic development and well-established healthcare infrastructure is fueling the overall regional market's growth to a large extent. Further, the German oral anticoagulants market held the largest market share, and the UK oral anticoagulants market was the fastest-growing market in the European region.
The Asia-Pacific Oral Anticoagulants Market will likely grow at the fastest CAGR from 2024 - 2032. This region's increased awareness of cardiovascular diseases and rising disposable income drive market growth. There are many options for advanced anticoagulant drugs (also known as blood thinners) to help patients feel better due to the prevalence of cardiovascular diseases. Moreover, China’s oral anticoagulants market held the largest market share, and the Indian oral anticoagulants market was the fastest-growing market in the Asia-Pacific region.
Oral Anticoagulants Key Market Players & Competitive Insights
Major market players have introduced oral anticoagulants to meet the urgent needs for treating blood clots. The oral anticoagulants industry is mature, with many generics available, particularly for older product launches. New entrants face challenges as they must adhere to all drug formulations created by various associations and refrain from deviating from them. The oral anticoagulants market’s major players, such as Pfizer (US), Abbott Laboratories (US), AstraZeneca Plc (UK), and others, are investing in R&D to increase the number of pipeline medications.
The oral anticoagulants industry has recently provided novel oral and topical drugs that offer some of the most significant advantages. Key players are also pursuing various strategic market developments initiative to expand their footprint, including new product introductions, contractual agreements, mergers and acquisitions, R&D investments, and collaborative projects with other organizations. Commercializing anticoagulant products is a priority for governments and private players. Additionally, oral anticoagulants industry manufacturers are concentrating on increasing their presence in developing nations like India, Brazil, South Africa, China, and Mexico to expand business operations and look for new markets.
Mylan N.V. is a multinational pharmaceutical company specializing in generic and specialty drugs. In addition to operating a manufacturing facility for active pharmaceutical ingredients, the company also manages a specialty division focusing on allergy, respiratory, and psychiatric therapies. Mylan N.V. declared it would pay Aspen USD 756 million in September 2020 to expand the sterile oral anticoagulants available in Europe. This agreement will assist the business in increasing its hospital clientele and accelerating the development of their biosimilars brand in Europe.
Also, Twist Bioscience, based in South San Francisco, is a public biotechnology company that produces synthetic DNA and DNA products for customers in various industries. In October 2021, Boehringer Ingelheim International GmbH and Twist Bioscience, a high-quality artificial DNA supplier, entered into a broad research partnership to use Twist Bioscience's proprietary antibody libraries to identify the therapeutic relationship of antibodies against various Boehringer Ingelheim targets.
Key Companies in the oral anticoagulants market include
Oral Anticoagulants Industry Developments
February 2022Â Techdow USA Inc, a vertically integrated standardized injectables company, introduced Heparin Sodium Injection, USP, to the oral anticoagulants industry in the United States.
February 2021Â According to the Stony Brook study, critically ill Covid-19 patients had a lower mortality rate when receiving anticoagulation treatment based on their blood serum D-dimer levels.
September 2020Â Mylan N.V. announced the signing of an agreement to acquire Aspen Pharmacare Holdings Limited's European thrombosis business. The company will benefit from this acquisition by becoming the second-largest provider of oral anticoagulants product to European patients.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 22.76 billion |
| Market Size 2024 | USD 24.76 billion |
| Market Size 2032 | USD 38.1 billion |
| Compound Annual Growth Rate (CAGR) | 5.53% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered | Product, Disease Indication, Distribution Channel, and Region |
| Geographies Covered | Europe, North America, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Germany, Canada, U.K., Italy, France, Spain, Japan, China, Australia, India, South Korea, and Brazil |
| Key Companies Profiled | AstraZeneca Plc (UK), Pfizer (US), Boehringer Ingelheim GmbH (Germany), Daiichi Sankyo Company Ltd (Japan), Abbott Laboratories (US), Eli Lilly & Company (US), GlaxoSmithKline Plc (UK), Portola Pharmaceuticals Inc (US), Medicure (Canada), Johnson & Johnson Services Inc (US) |
| Key Market Opportunities | Increasing R&D spending in the pharmaceutical industry Emerging demands for novel therapeutics |
| Key Market Dynamics | Increased prevalence of heart diseases and venous thromboembolism (VTE) Introduction of novel oral anticoagulants drugs |
Oral Anticoagulants Market Highlights:
Frequently Asked Questions (FAQ) :
The oral anticoagulants market size was valued at USD 22.76 Billion in 2023.
The market is anticipated to grow at a CAGR of 5.53% in the forecast period, 2024-2032.
North America held the largest revenue share of the market.
The key players in the market are Pfizer (US), AstraZeneca Plc (UK), Boehringer Ingelheim GmbH (Germany), Daiichi Sankyo Company Ltd (Japan), Abbott Laboratories (US), Eli Lilly & Company (US), GlaxoSmithKline Plc (UK), Portola Pharmaceuticals Inc (US), Medicure (Canada), and Johnson & Johnson Services Inc (US).
The novel oral anticoagulant category dominated the market in 2023.
Pulmonary Embolism (PE) had the most significant market share.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
